Cyproheptadine-Induced Remission of Cushingʼs Disease

Krieger, Dorothy T.; Amorosa, Louis F.; Linick, Frederica

doi:10.1097/00006254-197605000-00017

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the medical treatment of patients with Cushing's disease and Nelson's syndrome, bromocriptine (Lamberts & Birkenhager, 1976) and cyproheptadine (Krieger et al, 1975) have been reported to be effective in controlling hypersecretion of ACTH, but only some respond to these drugs and surgical adenomectomy often fails to cure the disease completely (Ludecke et al, 1982).…”

mentioning

confidence: 99%

Unaltered Stimulation of Pituitary Adrenocorticotrophin Secretion by Corticotrophin‐releasing Factor Following Sodium Valproate Administration in a Patient With Nelson's Syndrome

Gomi

Iida

Itoh

et al. 1985

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Unaltered Stimulation of Pituitary Adrenocorticotrophin Secretion by Corticotrophin‐releasing Factor Following Sodium Valproate Administration in a Patient With Nelson's Syndrome

Gomi

Iida

Itoh

et al. 1985

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…) is a serotonin and histamine antagonist with anticholinergic and sedative effects. Histamine is a biochemical mediator of inflammation that works through binding to special histamine receptors . The histamine receptors usually inactivated in combating allergic reactions are called H1 receptors, and these are inactivated by CYP.…”

Section: Introductionmentioning

confidence: 99%

“…The molecular interactions between HSA and many compounds have been investigated successfully, including many drugs . In addition, there are many reports in the literature about the pharmacology and pharmacodynamics of CYP . However, to the best of our knowledge, a detailed investigation of the HSA‐CYP binding mechanism has not been reported in the literature.…”

Section: Introductionmentioning

confidence: 99%

Interaction of cyproheptadine hydrochloride with human serum albumin using spectroscopy and molecular modeling methods

et al. 2012

View full text Add to dashboard Cite

The interaction between cyproheptadine hydrochloride (CYP) and human serum albumin (HSA) was investigated by fluorescence spectroscopy, UV-vis absorption spectroscopy, Fourier transform infrared spectroscopy (FT-IR) and molecular modeling at a physiological pH (7.40). Fluorescence of HSA was quenched remarkably by CYP and the quenching mechanism was considered as static quenching since it formed a complex. The association constants Ka and number of binding sites n were calculated at different temperatures. According to Förster's theory of non-radiation energy transfer, the distance r between donor (human serum albumin) and acceptor (cyproheptadine hydrochloride) was obtained. The effect of common ions on the binding constant was also investigated. The effect of CYP on the conformation of HSA was analyzed using FT-IR, synchronous fluorescence spectroscopy and 3D fluorescence spectra. The thermodynamic parameters ΔH and ΔS were calculated to be -14.37 kJ mol(-1) and 38.03 J mol(-1) K(-1), respectively, which suggested that hydrophobic forces played a major role in stabilizing the HSA-CYP complex. In addition, examination of molecular modeling indicated that CYP could bind to site I of HSA and that hydrophobic interaction was the major acting force, which was in agreement with binding mode studies.

show abstract